Abstract
The use of inhaled, fixed-dose, long-acting muscarinic antagonists (LAMA) combined with long-acting, beta2-adrenergic receptor agonists (LABA) has become a mainstay in the maintenance treatment of chronic obstructive pulmonary disease (COPD). One of the fixed-dose LAMA/LABA combinations is the dry powder inhaler (DPI) of umeclidinium bromide (UMEC) and vilanterol trifenatate (VI) (62.5 µg/25 µg) approved for once-a-day maintenance treatment of COPD. This paper reviews the use of fixed-dose combination LAMA/LABA agents focusing on the UMEC/VI DPI inhaler in the maintenance treatment of COPD. The fixed-dose combination LAMA/LABA inhaler offers a step beyond a single inhaled maintenance agent but is still a single device for the COPD patient having frequent COPD exacerbations and persistent symptoms not well controlled on one agent. Currently available clinical trials suggest that the once-a-day DPI of UMEC/VI is well-tolerated, safe and non-inferior or better than other currently available inhaled fixed-dose LAMA/LABA combinations for COPD.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1251-1265 |
| Number of pages | 15 |
| Journal | International journal of chronic obstructive pulmonary disease |
| Volume | 14 |
| DOIs | |
| State | Published - Jan 1 2019 |
Fingerprint
Keywords
- COPD
- fixed-dose combination inhalers
- LABA
- LAMA
- long-acting beta2-adrenergic agonists
- long-acting muscarinic antagonists
- umeclidinium bromide
- vilanterol trifenatate
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
- Health Policy
- Public Health, Environmental and Occupational Health
Cite this
Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD. / Albertson, Timothy E; Bowman, Willis S.; Harper, Richart W; Godbout, Regina M.; Murin, Susan.
In: International journal of chronic obstructive pulmonary disease, Vol. 14, 01.01.2019, p. 1251-1265.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD
AU - Albertson, Timothy E
AU - Bowman, Willis S.
AU - Harper, Richart W
AU - Godbout, Regina M.
AU - Murin, Susan
PY - 2019/1/1
Y1 - 2019/1/1
N2 - The use of inhaled, fixed-dose, long-acting muscarinic antagonists (LAMA) combined with long-acting, beta2-adrenergic receptor agonists (LABA) has become a mainstay in the maintenance treatment of chronic obstructive pulmonary disease (COPD). One of the fixed-dose LAMA/LABA combinations is the dry powder inhaler (DPI) of umeclidinium bromide (UMEC) and vilanterol trifenatate (VI) (62.5 µg/25 µg) approved for once-a-day maintenance treatment of COPD. This paper reviews the use of fixed-dose combination LAMA/LABA agents focusing on the UMEC/VI DPI inhaler in the maintenance treatment of COPD. The fixed-dose combination LAMA/LABA inhaler offers a step beyond a single inhaled maintenance agent but is still a single device for the COPD patient having frequent COPD exacerbations and persistent symptoms not well controlled on one agent. Currently available clinical trials suggest that the once-a-day DPI of UMEC/VI is well-tolerated, safe and non-inferior or better than other currently available inhaled fixed-dose LAMA/LABA combinations for COPD.
AB - The use of inhaled, fixed-dose, long-acting muscarinic antagonists (LAMA) combined with long-acting, beta2-adrenergic receptor agonists (LABA) has become a mainstay in the maintenance treatment of chronic obstructive pulmonary disease (COPD). One of the fixed-dose LAMA/LABA combinations is the dry powder inhaler (DPI) of umeclidinium bromide (UMEC) and vilanterol trifenatate (VI) (62.5 µg/25 µg) approved for once-a-day maintenance treatment of COPD. This paper reviews the use of fixed-dose combination LAMA/LABA agents focusing on the UMEC/VI DPI inhaler in the maintenance treatment of COPD. The fixed-dose combination LAMA/LABA inhaler offers a step beyond a single inhaled maintenance agent but is still a single device for the COPD patient having frequent COPD exacerbations and persistent symptoms not well controlled on one agent. Currently available clinical trials suggest that the once-a-day DPI of UMEC/VI is well-tolerated, safe and non-inferior or better than other currently available inhaled fixed-dose LAMA/LABA combinations for COPD.
KW - COPD
KW - fixed-dose combination inhalers
KW - LABA
KW - LAMA
KW - long-acting beta2-adrenergic agonists
KW - long-acting muscarinic antagonists
KW - umeclidinium bromide
KW - vilanterol trifenatate
UR - http://www.scopus.com/inward/record.url?scp=85068874913&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068874913&partnerID=8YFLogxK
U2 - 10.2147/COPD.S191845
DO - 10.2147/COPD.S191845
M3 - Review article
VL - 14
SP - 1251
EP - 1265
JO - International Journal of COPD
JF - International Journal of COPD
SN - 1176-9106
ER -